Sanofi-Aventis, Cegedim Dendrite join forces

Share this article:
Cegedim Dendrite inked a three-year agreement with Sanofi-Aventis to provide Mobile Intelligence CRM solution to over 20,000 users across 28 countries including the US, France and Japan.

Laurent Labrune, CEO of Cegedim Dendrite, said that his company has demonstrated the best capability to proactively support Sanofi-Aventis' business model evolution toward multichannel CRM, key account and KOL management, with the lowest investment.

Labrune added that the integration of Mobile Intelligence Solution with OneKey will enable Sanofi-Aventis to benefit from a unique database on a worldwide scale, gaining the company an optimized ROI on data management.

The solution has just been deployed for the managed markets group in the US, France and Spain will follow in the first quarter of 2010.

Cegedim Dendrite is a provider of customer relationship management solutions.

The company also provides sales, marketing and regulatory compliance solutions in more than 80 countries.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?